NasdaqGS - Nasdaq Real Time Price USD

Erasca, Inc. (ERAS)

20.78 +1.27 (+6.54%)
As of 11:10:45 AM EDT. Market Open.
Trade Erasca on Coinbase
Chart Range Bar
Loading chart for ERAS
  • Previous Close 19.50
  • Open 19.46
  • Bid 14.78 x 200
  • Ask 24.92 x 200
  • Day's Range 19.46 - 20.83
  • 52 Week Range 1.33 - 24.28
  • Volume 2,511,591
  • Avg. Volume 6,909,965
  • Market Cap (intraday) 6.461B
  • Beta (5Y Monthly) 0.67
  • PE Ratio (TTM) --
  • EPS (TTM) -0.93
  • Earnings Date May 11, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 21.00

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agreement with Guangzhou Joyo Pharmatech Co., Ltd to develop, manufacture, and commercialize certain pan-RAS inhibitors; Medshine Discovery Inc. to develop, manufacture, and commercialize certain pan-KRAS inhibitors; Novartis Pharma AG to develop, manufacture, use, and commercialize naporafenib; NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds; and Asana BioSciences, LLC to develop and commercialize ERAS-007 and certain other related compounds. The company has a clinical trial collaboration and supply agreement with Tango Therapeutics, Inc. for the evaluation of ERAS-0015. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

www.erasca.com

103

Full Time Employees

December 31

Fiscal Year Ends

Performance Overview

Trailing total returns as of 7/15/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

ERAS
458.47%
S&P 500 (^GSPC)
10.49%

1-Year Return

ERAS
1,373.40%
S&P 500 (^GSPC)
21.14%

3-Year Return

ERAS
689.92%
S&P 500 (^GSPC)
67.88%

5-Year Return

ERAS
30.66%
S&P 500 (^GSPC)
73.48%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized
 

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue --
Earnings -183.44M

Q2

FY25

Q3

FY25

Q4

FY25

Q1

FY26

-150M
-100M
-50M
0
 

Analyst Insights

View More

Analyst Price Targets

12.00 Low
21.00 Average
20.77 Current
30.00 High
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Latest Rating

Date 7/14/2026
Analyst B of A Securities
Rating Action Maintains
Rating Neutral
Price Action Raises
Price Target 16 -> 18
 

Statistics

View More

Valuation Measures

Annual
As of 7/14/2026
  • Market Cap

    6.06B

  • Enterprise Value

    5.87B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    15.41

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -17.92%

  • Return on Equity (ttm)

    -69.86%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -277.02M

  • Diluted EPS (ttm)

    -0.93

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    243.79M

  • Total Debt/Equity (mrq)

    11.68%

  • Levered Free Cash Flow (ttm)

    -212.71M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

20.77 Current
 

Dividend Score

0 Low
Sector Avg.
100 High
 

Hiring Score

0 Low
Sector Avg.
100 High
 

Insider Sentiment Score

0 Low
Sector Avg.
100 High
 

People Also Watch